On July 30, 2026, DFZQ bought 203,500 shares of KEYMED BIO-B at an average of HKD 72.8753 per share, involving about HKD 14.83 million.
Prior to the acquisition, DFZQ's long position in KEYMED BIO-B was 14.89 million shares, representing 4.98%; following the acquisition, the holding changed to 15.10 million shares, with the long position ratio rising to 5.05%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments